MBMaximilian Bockhorn

Maximilian Bockhorn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maximilian Bockhorn has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Overall Survival after Pancreaticoduodenectomy with Portal Vein Resection for Macroscopically Infiltrating Pancreatic Cancer

    by Ramez Wahib, Michael F. Nentwich, Matthias Reeh, Pasquale Scognamiglio, Florian Gebauer, Maximilian Bockhorn, Jakob R. Izbicki, Dean Bogoevski

    • 1 August 2016
      • Vol. 36  (8) , 3991-5

    Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma.

    by Robin Wachowiak, Steffi Mayer, Jussuf Kaifi, Florian Gebauer, Jakob R Izbicki, Martin Lacher, Maximilian Bockhorn, Michael Tachezy

    Activated leukocyte cell adhesion molecule (ALCAM/CD166) as a member of the 'immunoglobulin superfamily' is known to be involved in cancer cell proliferation and migration. The aim of this study was to investigate the expression of ALCAM in neuroblastoma tissues. ALCAM expression was analyzed in primary neuroblastoma specimens by immunohistochemistry on microarray sections. Histopathological and clinical data were correlated with ALCAM expression and survival analysis was performed. Sixty-six children were included in the study. Strong expression of ALCAM was detected in 52 (79%) of the samples. Weak expression was significantly correlated with the International Neuroblastoma Staging System (INSS) stage (p=0.024) and positive n-MYC amplification (p=0.019). Recurrence-free survival (RFS) and overall survival (OS) were significantly shorter if ALCAM was expressed weakly (p=0.032 and p=0.001). Weak ALCAM expression was significantly correlated with established markers for poor prognosis, as well as shorter RFS and OS. ALCAM might be considered as a prognostic marker for infantile neuroblastoma.


    • 1 November 2013
      • Vol. 33  (11) , 4975-82

    Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.

    by Alexandra M König, Matthias Reeh, Ana-Maria Dancau, Merrit Rathjens, Stephanie Gros, Faik G Uzunoglu, Maximilian Bockhorn, Ronald Simon, Guido Sauter, Andreas Marx, et al.

    Human epidermal growth factor receptor 2 (HER2) is an important prognostic factor in several types of solid tumours. Although HER2 seems not to influence survival in esophageal carcinomas, an impact of the HER2 status of disseminated tumour cells (DTCs) on survival has been shown. The aim of our study was to investigate the significance of the HER2 status in primary esophageal carcinomas and matched lymph node metastases. The HER2 status of primary tumours and matched lymph node metastases were analysed for 158 patients with esophageal carcinoma using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH). The study specimen included 90 adenocarcinomas (AC) and 68 squamous cell carcinomas (SCC). HER2 amplification was found in 12% and overexpression in 8.9% of all primary tumours. HER2 amplification was identical in the primary tumour and lymph node metastases in all AC and in 75% of SCC. Discordant-positive HER2 lymph node status and negative primary tumour status was found in 4.4% of AC and 1.5% of SCC in FISH analyses. No significant associations were found between HER2 amplification/overexpression and overall survival. HER2 gene status remains highly conserved in metastatic esophageal carcinoma. Discrepancies occur rarely between primary tumour and lymph node metastases and might be due to heterogeneity of the HER2 status of the primary tumour. This could be the reason for heterogeneity of DTCs and may result in metastasis of only a subset of tumour cells.


  • Periinterventionelles Gerinnungsmanagement

    by Maximilian Bockhorn, Ansgar W. Lohse, Jacob R. Izbicki

    Thromboseprophylaxe, Thrombosetherapie und Blutgerinnungsstörungen sollten zum Behandlungsrepertoire eines jeden Viszeralmediziners gehören. Dies mag angesichts der Komplexität der Gerinnungsmechanismen und der komplizierten pharmakologischen Wirkungsweisen der Gerinnungsmedikamente ein sehr hoher Anspruch sein, der sich aber relativiert, wenn die Folgen einer unsachgemäßen oder unzureichenden Gerinnungsmedikation betrachtet werden:

  • Options and Limitations in Applying the Fistula Classification by the International Study Group for Pancreatic Fistula

    by Florian Gebauer, Katja Bsc Kloth, Michael Tachezy, Yogesh K. Vashist, Guellue Cataldegirmen, Jakob R. Md Izbicki, Maximilliam Bockhorn

    Background: Because of its retrospective character, the classification system of the International Study Group of Pancreatic Fistula (ISGPF) lacks prognostic capacity regarding fistula-related complications. This study aimed to evaluate the options and limitations of the ISGPF classification system and to identify risk factors with respect to clinical decision making. Methods: Between 1992 and 2009, 1966 patients underwent surgery of the pancreas. All patient data were entered into a prospective clinical data management system. Results: After surgery, 276 patients (14%) developed postoperative pancreatic fistula (POPF). ISGPF type A fistula was seen in 69 patients (25%), type B in 110 (39.9%), and type C in 97 (34.1%). Solely due to their death, 16 patients had to be classified as type C fistula, even though they suffered only type A or B. Compared to genuine C fistulas, we were not able to detect any significant predictors, which may allow to distinguish the development in their further clinical course. The level of drainage amylase is of no use, whereas univariate analysis identified underlying disease, type of operation, and high levels of serum amylase or bilirubin on the day of onset of POPF to be prognostic parameters for reoperation. Multivariate analysis found elevated serum C-reactive protein to be an independent factor for increased in-hospital mortality. Conclusions: The ISGPF classification system has its limitations in clinical decision making, because it does not adequately describe a large subgroup of patients. To improve clinical decision making about management of patients, it is crucial that the ISGPF classification system is merged with newer clinical data.


    • 1 May 2012
      • Vol. 32  (5) , 1999-2002

    Surgery for advanced and metastatic pancreatic cancer--current state and trends.

    by Michael F. Nentwich, Maximilian Bockhorn, Alexandra König, Jakob R Izbicki, Güllü Cataldegirmen

    Due to the late onset of symptoms in pancreatic cancer, patients are often presented with an already advanced or metastatic state of disease. Only in a minority of patients is a tumor resection indicated, e.g. in general tumor encasement of major vessels, while the presence of metastatic disease excludes patients from curative-intended surgery. Limitations for pancreatic resections have been debated and re-thought after more experience has gained over time. This holds true for en-bloc vascular resections, total pancreatectomies, intentional R2 pancreatic resections and synchronous resection of liver metastases. These issues are addressed in this review.


  • Advanced Esophageal Carcinoma: Is It Still Worth to Operate?

    by Dean Bogoevski, Matthias Reeh, Maximilian Bockhorn, Alexandra M. Koenig, Asad R. Kutup, Thomas Roesch, Jakob Izbicki

  • Replicative Stress-Induced Midkine Expression and Secretion Activates Notch Signaling and is Linked to Epithelial-Mesenchymal Transition and Chemoresistance in Pancreatic Cancer

    by Cenap Güngor, Hilke Zander, Florian Gebauer, Michael Tachezy, Emre F. Yekebas, Jakob R. Izbicki, Maximilian Bockhorn

  • Open Access

    Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung

    by Tatyana Kalinina, Cenap Güngör, Sabrina Thieltges, Maren Möller-Krull, Eva Maria Murga Penas, Daniel Wicklein, Thomas Streichert, Udo Schumacher, Viacheslav Kalinin, Ronald Simon, et al.

    Pancreatic cancer is still associated with devastating prognosis. Real progress in treatment options has still not been achieved. Therefore new models are urgently needed to investigate this deadly disease. As a part of this process we have established and characterized a new human pancreatic cancer cell line.


  • Crossing the Rubicon: When Pancreatic Resection with Curative Intent Ends in an R2 Status

    by Maximilian Bockhorn, Guellue Cataldegirmen, Asad Kutup, Andreas Marx, Christoph Burdelski, Jogesh K. Vashist, Oliver Mann, Lena Liebl, Alexandra König, Jakob R. Izbicki, et al.

    To analyze the impact of pancreatitis-mimicking, concomitant alterations on intraoperative assessment of curative resectability, the anatomical site of irresectability, and outcome after nonintentional R2 resection in pancreatic cancer. Of 1,099 patients subjected to pancreatic resection for cancer, 40 (4%) underwent R2 resection (group A). The site where tumors turned out to be irresectable and the coincident presence of potentially misleading, fibro-desmoplastic alterations were analyzed. Outcome after resection was compared with 40 bypass patients matched for age, gender, histopathology, and use of additive chemotherapy (group B). R2 resection was due to misjudgment regarding resectability in 38 patients (95%) and to uncontrollable hemorrhage in 2 patients (5%). Group A patients had significantly longer operative times (P < 0.0001), required more blood units (P < 0.0001), and had longer hospital stay than group B patients (P = 0.049). Despite a significantly higher relaparotomy rate of 20% (n = 8) in group A versus 5% (n = 2) in group B, perioperative mortality was equal (n = 2, each). Median survival was 11.5 months in group A and 7.5 months in group B (P = 0.014). "Pancreatitis-like" lesions were assessed in 70% (n = 28/40, group A) and 25% (10/40, group B; P = 0.014). The superior mesenteric artery proximal to its jejunal branches was the most likely site of irresectability (60%), followed by its peripheral course (22.5%) and the lower aspects of the celiac trunk (17.5%). Concomitant "pancreatitis-like" alterations hamper the assessment of local resectability in pancreatic cancer. Although palliative resection results in elevated perioperative morbidity compared with bypass procedures, mortality is equal, while survival is prolonged.